Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 May 6;22(1):503.
doi: 10.1186/s12885-022-09385-8.

A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study

Kazuki Takada #  1 , Mototsugu Shimokawa #  2   3 , Shinkichi Takamori #  4 , Shinichiro Shimamatsu  5 , Fumihiko Hirai  5 , Tetsuzo Tagawa  6 , Tatsuro Okamoto  7 , Motoharu Hamatake  5 , Yuko Tsuchiya-Kawano  8 , Kohei Otsubo  8 , Koji Inoue  8 , Yasuto Yoneshima  9 , Kentaro Tanaka  9 , Isamu Okamoto  9 , Yoichi Nakanishi  8 , Masaki Mori  6
Affiliations
Multicenter Study

A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study

Kazuki Takada et al. BMC Cancer. .

Abstract

Background: Many studies have recently reported the association of concomitant medications with the response and survival in patients with non-small-cell lung cancer (NSCLC) treated with cancer immunotherapy. However, the clinical impact of statin therapy on the outcome of cancer immunotherapy in patients with NSCLC is poorly understood.

Methods: In our database, we retrospectively identified and enrolled 390 patients with advanced or recurrent NSCLC who were treated with anti-programmed cell death-1 (PD-1) monotherapy in clinical practice between January 2016 and December 2019 at 3 medical centers in Japan to examine the clinical impact of statin therapy on the survival of patients with NSCLC receiving anti-PD-1 monotherapy. A propensity score-matched analysis was conducted to minimize the bias arising from the patients' backgrounds.

Results: The Kaplan-Meier curves of the propensity score-matched cohort showed that the overall survival (OS), but not the progression-free survival (PFS), was significantly longer in patients receiving statin therapy. However, a Cox regression analysis in the propensity score-matched cohort revealed that statin therapy was not an independent favorable prognostic factor, although it tended to be correlated with a favorable outcome.

Conclusions: Statin therapy may be a combination tool for cancer immunotherapy in patients with NSCLC. These findings should be validated in further prospective studies with larger sample sizes.

Keywords: Nivolumab; Non-small-cell lung cancer; Pembrolizumab; Prognostic factor; Statin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
CONSORT diagram of this study. PD-1, programmed cell death-1
Fig. 2
Fig. 2
Kaplan–Meier curves of (a) progression-free survival and (b) overall survival according to statin therapy in the propensity score-matched cohort. CI, confidence interval; OS, overall survival; PFS, progression-free survival
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G, Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet (London, England) 2019;393(10183):1819–1830. - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung Cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–546. - PubMed
    1. Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro CJ, Pluzanski A, Arrieta O, Frontera OA, Chiari R, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus Docetaxel in previously treated non-small-cell lung Cancer. J Clin Oncol. 2021;39(7):723–733. doi: 10.1200/JCO.20.01605. - DOI - PMC - PubMed
    1. Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437–1444. - PMC - PubMed
    1. Afzal MZ, Dragnev K, Sarwar T, Shirai K. Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors. Lung Cancer Manag. 2019;8(2):Lmt11. - PMC - PubMed

Publication types

MeSH terms

Substances